Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 167
Filtrar
Más filtros

Medicinas Tradicionales
Medicinas Complementárias
Tipo del documento
Intervalo de año de publicación
1.
Pak J Biol Sci ; 26(3): 108-118, 2023 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-37480267

RESUMEN

<b>Background and Objective:</b> The emergence of antibiotic resistance is a primary global health concern. As a result, there is an urgent need for new strategies to combat antibiotic-resistant bacteria. One of these essential strategies is the combination of medicinal plants and antibiotics as an alternative to using antibiotics alone which was the objective of this article. <b>Materials and Methods:</b> Nine plant materials were collected from different Egypt localities and then extracted by water. Water extracts were filtered and added with Mueller-Hinton agar during preparation. Nine test bacteria and 13 standard antibiotics were used in the disc diffusion sensitivity method. <b>Results:</b> The activity of Amikacin was increased when combined with most different plant extracts against <i>Escherichia coli</i> while antagonistic against <i>Pseudomonas aeruginosa</i>. Aztreonam, Ceftriaxone, Gentamicin and Nalidixic acid antibiotics showed antagonistic or indifferent effects when combined with most different plant extracts against <i>E. coli</i>, <i>Klebsiella pneumonia</i> and <i>P. aeruginosa</i>. The synergistic effect was achieved in Aztreonam when combined with all plant extracts, while Nalidixic acid showed antagonistic when combined with most plant extracts against <i>Proteus mirabilis</i>. The antagonistic effect was achieved in Aztreonam, Ceftriaxone and Nalidixic acid when combined with <i>Achillea fragrantissima</i>, <i>Artemisia monosperma</i> and <i>Leptadenia pyrotechnica</i>, also Aztreonam with <i>Lycium shawii</i> extract against <i>Salmonella typhimurium</i>. The <i>A. fragrantissima</i> and <i>A. monosperma</i> increase the activity of Novobiocin and Vancomycin against <i>Bacillus cereus</i> and Ampicillin and Cefazolin against <i>Staphylococcus aureus</i> but Novobiocin activity increased with most plant extracts against <i>S. aureus</i>. <b>Conclusion:</b> The combinations of antibiotics with the extracts of medicinal plants displayed varying degrees of effects, synergistic, antagonistic and indifferent according to antibiotic type, plant extract and test organism.


Asunto(s)
Antibacterianos , Plantas Medicinales , Antibacterianos/farmacología , Aztreonam , Ceftriaxona , Ácido Nalidíxico , Novobiocina , Escherichia coli , Staphylococcus aureus , Extractos Vegetales/farmacología , Bacillus cereus
2.
mBio ; 13(5): e0193622, 2022 10 26.
Artículo en Inglés | MEDLINE | ID: mdl-36073813

RESUMEN

The Gram-negative anaerobe Fusobacterium nucleatum is a major producer of hydrogen sulfide (H2S), a volatile sulfur compound that causes halitosis. Here, we dissected the genetic determinants of H2S production and its role in bacterial fitness and virulence in this important member of the oral microbiome. F. nucleatum possesses four enzymes, CysK1, CysK2, Hly, and MegL, that presumably metabolize l-cysteine to H2S, and CysK1 was previously shown to account for most H2S production in vitro, based on correlations of enzymatic activities with gene expression at mid-log phase. Our molecular studies showed that cysK1 and megL were highly expressed at the late exponential growth phase, concomitant with high-level H2S production, while the expression levels of the other genes remained substantially lower during all growth phases. Although the genetic deletion of cysK1 without supplementation with a CysK1-catalyzed product, lanthionine, caused cell death, the conditional ΔcysK1 mutant and a mutant lacking hly were highly proficient in H2S production. In contrast, a mutant devoid of megL showed drastically reduced H2S production, and a cysK2 mutant showed only minor deficiencies. Intriguingly, the exposure of these mutants to various antibiotics revealed that only the megL mutant displayed altered susceptibility compared to the parental strain: partial sensitivity to nalidixic acid and resistance to kanamycin. Most significantly, the megL mutant was attenuated in virulence in a mouse model of preterm birth, with considerable defects in the spread to amniotic fluid and the colonization of the placenta and fetus. Evidently, the l-methionine γ-lyase MegL is a major H2S-producing enzyme in fusobacterial cells that significantly contributes to fusobacterial virulence and antibiotic susceptibility. IMPORTANCE Fusobacterium nucleatum is a key commensal anaerobe of the human oral cavity that plays a significant role in oral biofilm development and contributes to additional pathologies at extraoral sites, such as promoting preterm birth and colorectal cancer. Although F. nucleatum is known as a major producer of hydrogen sulfide (H2S), its genetic determinants and physiological functions are not well understood. By a combination of bacterial genetics, biochemical methods, and in vivo models of infection, here, we demonstrate that the l-methionine γ-lyase MegL not only is a major H2S-producing enzyme of F. nucleatum but also significantly contributes to the antibiotic susceptibility and virulence of this organism.


Asunto(s)
Sulfuro de Hidrógeno , Nacimiento Prematuro , Recién Nacido , Embarazo , Ratones , Animales , Femenino , Humanos , Fusobacterium nucleatum , Sulfuro de Hidrógeno/metabolismo , Virulencia , Cisteína/metabolismo , Antibacterianos/farmacología , Antibacterianos/metabolismo , Ácido Nalidíxico/metabolismo , Compuestos de Azufre , Kanamicina/metabolismo
3.
J Infect Dev Ctries ; 15(4): 579-583, 2021 04 30.
Artículo en Inglés | MEDLINE | ID: mdl-33956660

RESUMEN

INTRODUCTION: With increasing fluoroquinolone resistance, extended spectrum cephalosporins are recommended for the treatment of invasive Salmonella infections. However, Extended spectrum beta-lactamases (ESBL) producing Salmonella Paratyphi A causing enteric fever is on the rise and constitutes a major therapeutic challenge. Hence, we aimed to assess the incidence of ESBL production, fluoroquinolone resistance in S. Paratyphi A and to compare the fluoroquinolone resistance detection methods. METHODOLOGY: Seventeen blood-culture isolates of S. Paratyphi A were tested for susceptibility to ampicillin, chloramphenicol, co-trimoxazole, streptomycin and tetracycline (ACCuST), fluoroquinolones, azithromycin and ceftriaxone by disk diffusion method. We compared and correlated between disk diffusion of ciprofloxacin and pefloxacin with ciprofloxacin MIC. Combined disk test was employed to determine ESBL production. RESULTS: In this study, 13(76.5%) isolates were nalidixic acid resistant (NAR), 16 (94.1%) were pefloxacin resistant, while 7 (41.2%), 9 (52.9%) exhibited resistance and intermediate susceptibility to ciprofloxacin respectively. The MIC50, MIC90 of ciprofloxacin was 1 µg/mL, 2 µg/mL respectively. Among the NAR, 76.92% were DSC (MIC 0.5-1 µg/mL) and 23.08% had an MIC of 2-4 µg/mL. Of note, 4 isolates with DSC were NAS. Of the 17 S. Paratyphi A isolates, 14 (82.4%) were ESBL producers and 11 (64.7%) isolates were ceftriaxone susceptible. CONCLUSIONS: Multidrug resistant (AmpRChlRSxtR) S. Paratyphi A with combined resistance to fluoroquinolones and ESBL production is a cause of concern. We found S. Paratyphi A isolates with a relatively unusual phenotype: nalidixic acid susceptible but exhibited DSC; pefloxacin susceptible but ciprofloxacin resistant. Of note one multidrug resistant (AmpRChlRSxtR) isolate, an ESBL producer exhibited resistance to azithromycin, cephalosporins and fluoroquinolones but was susceptible to carbapenems and streptomycin.


Asunto(s)
Antibacterianos/uso terapéutico , Farmacorresistencia Bacteriana Múltiple/efectos de los fármacos , Fluoroquinolonas/uso terapéutico , Ácido Nalidíxico/uso terapéutico , Fiebre Tifoidea/microbiología , Antibacterianos/farmacología , Fluoroquinolonas/farmacología , Humanos , India , Pruebas de Sensibilidad Microbiana , Ácido Nalidíxico/farmacología , Salmonella paratyphi A/aislamiento & purificación , Fiebre Tifoidea/tratamiento farmacológico
4.
Nucleic Acids Res ; 49(2): e8, 2021 01 25.
Artículo en Inglés | MEDLINE | ID: mdl-33231685

RESUMEN

Whole-genome mapping technologies have been developed as a complementary tool to provide scaffolds for genome assembly and structural variation analysis (1,2). We recently introduced a novel DNA labeling strategy based on a CRISPR-Cas9 genome editing system, which can target any 20bp sequences. The labeling strategy is specifically useful in targeting repetitive sequences, and sequences not accessible to other labeling methods. In this report, we present customized mapping strategies that extend the applications of CRISPR-Cas9 DNA labeling. We first design a CRISPR-Cas9 labeling strategy to interrogate and differentiate the single allele differences in NGG protospacer adjacent motifs (PAM sequence). Combined with sequence motif labeling, we can pinpoint the single-base differences in highly conserved sequences. In the second strategy, we design mapping patterns across a genome by selecting sets of specific single-guide RNAs (sgRNAs) for labeling multiple loci of a genomic region or a whole genome. By developing and optimizing a single tube synthesis of multiple sgRNAs, we demonstrate the utility of CRISPR-Cas9 mapping with 162 sgRNAs targeting the 2Mb Haemophilus influenzae chromosome. These CRISPR-Cas9 mapping approaches could be particularly useful for applications in defining long-distance haplotypes and pinpointing the breakpoints in large structural variants in complex genomes and microbial mixtures.


Asunto(s)
Sistemas CRISPR-Cas , Mapeo Cromosómico/métodos , Cromosomas Bacterianos/genética , Haemophilus influenzae/genética , ARN Guía de Kinetoplastida/genética , Alelos , Secuencia de Bases , Benzoxazoles/análisis , Simulación por Computador , Secuencia Conservada/genética , ARN Polimerasas Dirigidas por ADN , Farmacorresistencia Bacteriana/genética , Colorantes Fluorescentes/análisis , Edición Génica/métodos , Genoma Bacteriano , Genoma Humano , Haemophilus influenzae/efectos de los fármacos , Haplotipos/genética , Humanos , Dispositivos Laboratorio en un Chip , Ácido Nalidíxico/farmacología , Novobiocina/farmacología , Motivos de Nucleótidos/genética , Polimorfismo de Nucleótido Simple , Compuestos de Quinolinio/análisis , ARN Guía de Kinetoplastida/síntesis química , Secuencias Repetitivas de Ácidos Nucleicos/genética , Alineación de Secuencia , Coloración y Etiquetado/métodos , Proteínas Virales
5.
Poult Sci ; 99(5): 2645-2649, 2020 May.
Artículo en Inglés | MEDLINE | ID: mdl-32359600

RESUMEN

Feed additives can be alternatives to antibiotics for routinely encountered pathogens in the poultry production. The objective of this study was to understand effects of organic acid mixture on growth parameters and Salmonella Typhimurium (ST) colonization in broilers. Organic acid mixture is a feed-grade buffered formic acid and sodium formate mixture (Amasil NA). A total of 800 1-day-old Cobb500 males were fed one of the five dietary treatments: a negative control diet without ST challenge (NC), positive control diet with ST challenge (PC), 0.3% organic acid mixture with ST, 0.6% organic acid mixture with ST, and 0.9% organic acid mixture with ST. Treatments were assigned to 20 pens with 40 chicks/pen and 4 replicates of each treatment. Chickens were challenged with 107 CFU/mL of nalidixic acid-resistant ST (STNAR) 4-D posthatch. In the grower phase, feed conversion rate was significantly reduced in the 9% organic acid mixture compared with the PC. The body weight and body weight gain (BWG) were not affected either in the starter or grower phases. However, in the finisher phase, the nonchallenged NC had higher BWG than the PC (P < 0.05), whereas there were no differences in BWG among the NC and organic acid mixture fed groups. In addition, there was a significant effect of organic acid mixture on the colonization of cecal STNAR. At 9 dpi, cecal STNAR was 3.28 log10 in the PC that was reduced to 2.65 log10 at 0.3%, 1.40 log10 at 0.6%, and 0.84 log10 in 0.9% organic acid mixture. At 24 dpi, cecal STNAR recovery was 0.81, 0.99, 0.53, and 0.33 log10 in the PC and 0.3, 0.6, and 0.9% organic acid mixture, respectively. Similarly, at 38 dpi, cecal STNAR was 0.26, 0.11, 0.33, and 0 log10 in the PC, 0.3, 0.6, and 0.9%, respectively. These results show that organic acid mixture can be one dietary strategy to control ST infection and maintain efficient growth performance.


Asunto(s)
Pollos , Formiatos/metabolismo , Enfermedades de las Aves de Corral/microbiología , Salmonelosis Animal/microbiología , Salmonella typhimurium/fisiología , Alimentación Animal/análisis , Animales , Antibacterianos/farmacología , Peso Corporal/efectos de los fármacos , Pollos/crecimiento & desarrollo , Dieta/veterinaria , Suplementos Dietéticos/análisis , Relación Dosis-Respuesta a Droga , Farmacorresistencia Bacteriana , Formiatos/administración & dosificación , Masculino , Ácido Nalidíxico/farmacología , Salmonella typhimurium/efectos de los fármacos , Aumento de Peso/efectos de los fármacos
6.
Int J Antimicrob Agents ; 55(5): 105909, 2020 May.
Artículo en Inglés | MEDLINE | ID: mdl-31991220

RESUMEN

OBJECTIVES: Since the early 2000s, Escherichia coli resistance to third-generation cephalosporins (3GCs) has been increasing in all European countries, mainly due to the spread of extended spectrum ß-lactamases (ESBLs). Here we present a retrospective study that combines resistance of E. coli to 3GCs and quinolones with data on antibiotic use in the community in a region of Northeastern France. METHODS: Since 2012, an observational surveillance of antimicrobial resistance and antibiotic use in the community was conducted: data on antimicrobial resistance in E. coli isolates were collected from 11 private laboratories, and consumption data were collected from the three main healthcare insurances. RESULTS: A significant decrease in the prevalence of resistance to 3GCs (from 5.6% to 4.2%; P < 0.001), nalidixic acid (from 16.7% to 14.8%; P = 0.004) and ciprofloxacin (from 10.9% to 8.1%; P < 0.001) was reported between 2015 and 2017. Although total antibiotic consumption did not vary significantly between 2012 and 2017, a decrease in the consumption of 3GCs (-32.%; P < 0.001) and quinolones (-25.5%; P < 0.001) was observed. CONCLUSION: Here we report a decrease in the prevalence of E. coli isolates resistant to 3GCs and quinolones in outpatients in the context of significant decreasing consumption of these two antibiotic classes.


Asunto(s)
Antibacterianos/uso terapéutico , Cefalosporinas/uso terapéutico , Ciprofloxacina/uso terapéutico , Farmacorresistencia Bacteriana/genética , Escherichia coli/efectos de los fármacos , Ácido Nalidíxico/uso terapéutico , Escherichia coli/genética , Escherichia coli/aislamiento & purificación , Infecciones por Escherichia coli/tratamiento farmacológico , Infecciones por Escherichia coli/epidemiología , Francia/epidemiología , Humanos , Pruebas de Sensibilidad Microbiana , Pacientes Ambulatorios/estadística & datos numéricos , Prevalencia , Estudios Retrospectivos , beta-Lactamasas/genética
7.
J Dermatol Sci ; 92(2): 188-196, 2018 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-30219520

RESUMEN

BACKGROUND: Atopic dermatitis (AD) is an inflammatory skin disease with an associated barrier dysfunction and Staphylococcus aureus infection. The mainstay steroid and calcineurin inhibitor therapy shows some adverse effects. 2,4-Dimethoxy-6-methylbenzene-1,3-diol (DMD) is a benzenoid isolated from Antrodia camphorata. OBJECTIVE: We investigated the inhibitory effect of DMD on methicillin-resistant S. aureus (MRSA), the chemokine production in stimulated keratinocytes, and the AD-like lesion found in ovalbumin (OVA)-sensitized mice. METHODS: The antimicrobial effect and cutaneous barrier function were evaluated using an in vitro culture model and an in vivo mouse model of AD-like skin. RESULTS: DMD exhibited a comparative minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) against MRSA with nalidixic acid, a conventional antibiotic. The MIC and MBC for DMD was 78.1 and 156.3 µg/ml, respectively. DMD also showed the ability to eliminate the clinical bacteria isolates with resistance to methicillin and vancomycin. The DNA polymerase and gyrase inhibition evoked by DMD for bacterial lethality was proposed. In the activated keratinocytes, DMD stopped the upregulation of chemokines (CCL5 and CCL17) and increased the expression of differentiation proteins (filaggrin, involucrin, and integrin ß-1). Topical application of DMD facilely penetrated into the skin, with AD-like skin displaying 2.5-fold greater permeation than healthy skin. The in vivo assessment using the mouse model with OVA sensitization and MRSA inoculation revealed a reduction of transepidermal water loss (TEWL) and bacterial burden by DMD by about 2- and 100-fold, respectively. Differentiation proteins were also restored after topical DMD delivery. CONCLUSION: Our data demonstrated an advanced concept of AD treatment by combined barrier repair and bacterial eradication with a sole agent for ameliorating the overall complications.


Asunto(s)
Antibacterianos/farmacología , Antrodia/química , Dermatitis Atópica/tratamiento farmacológico , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Infecciones Cutáneas Estafilocócicas/tratamiento farmacológico , Tolueno/análogos & derivados , Tolueno/farmacología , Administración Cutánea , Animales , Antibacterianos/aislamiento & purificación , Antibacterianos/uso terapéutico , Línea Celular , Quimiocinas/inmunología , Quimiocinas/metabolismo , Dermatitis Atópica/inmunología , Dermatitis Atópica/microbiología , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Proteínas Filagrina , Humanos , Staphylococcus aureus Resistente a Meticilina/aislamiento & purificación , Staphylococcus aureus Resistente a Meticilina/metabolismo , Ratones , Ratones Endogámicos BALB C , Pruebas de Sensibilidad Microbiana , Ácido Nalidíxico/farmacología , Ácido Nalidíxico/uso terapéutico , Ovalbúmina/inmunología , Piel/efectos de los fármacos , Piel/inmunología , Piel/metabolismo , Piel/microbiología , Infecciones Cutáneas Estafilocócicas/inmunología , Infecciones Cutáneas Estafilocócicas/microbiología , Porcinos , Tolueno/aislamiento & purificación , Tolueno/uso terapéutico , Resultado del Tratamiento , Pérdida Insensible de Agua/efectos de los fármacos
8.
Indian J Med Microbiol ; 36(1): 131-135, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29735844

RESUMEN

Therapeutic options with quinolones are severely compromised in infections caused by members of Enterobacteriaceae family. Mutations in chromosomal region are one of the major reasons for bacterial resistance towards this group of antibiotic. The aim of the study is to detect the mutations in gyr A and par C responsible for quinolone resistance among clinical isolates of Escherichia coli. A total of 96 quinolone-resistant clinical isolates of E. coli were collected from a tertiary care hospital of North-east India during March 2015 to August 2015. All the quinolone-resistant E. coli strains were investigated for mutations in the topoisomerases genes gyrA and parC by amplifying and sequencing the quinolone resistance determining regions. Among the 96 E. coli isolates, 83.3% were resistant to nalidixic acid and 80.2%, 66.6%, 23.9% and 50% to ciprofloxacin, norfloxacin, levofloxacin and ofloxacin, respectively. Several alterations were detected in gyrA and parC genes. Three new patterns of amino acid substitution are reported in E. coli isolates. The findings of this study warrant a review in quinolone-based therapy in this region of the world to stop or slow down the irrational use this drug.


Asunto(s)
Antibacterianos/uso terapéutico , Girasa de ADN/genética , Topoisomerasa de ADN IV/genética , Farmacorresistencia Bacteriana/genética , Escherichia coli/efectos de los fármacos , Escherichia coli/genética , Fluoroquinolonas/uso terapéutico , Ácido Nalidíxico/uso terapéutico , Escherichia coli/aislamiento & purificación , Infecciones por Escherichia coli/tratamiento farmacológico , Infecciones por Escherichia coli/microbiología , Humanos , India , Pruebas de Sensibilidad Microbiana , Centros de Atención Terciaria
9.
Trop Doct ; 48(3): 182-188, 2018 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-29495943

RESUMEN

The epidemiology of typhoid fever in South Asia has changed. Multi-drug resistant (MDR) Salmonella typhi ( S. typhi) is now frequently resistant to nalidixic acid and thus labelled NARST. Treatment failure with the use of fluoroquinolones has been widely noted, forcing clinicians to adopt alternative treatment strategies. In this observational study, we looked at various treatment regimens and correlated clinical and microbiological outcomes. In 146 hospitalised adults, the median minimum inhibitory concentration (MIC) for ciprofloxacin was 0.38 µg/mL with a median fever clearance time (FCT) of eight days (range = 2-35 days). Of the regimens used, gatifloxacin and azithromycin had a shorter FCT of six days compared to ceftriaxone (ten days; P < 0.001). Though mortality and relapse in our cohort was low, NARST seemed to correlate with mortality ( P = 0.006). Gatifloxacin or azithromycin clearly emerge as the drugs of choice for treatment of typhoid in South India.


Asunto(s)
Antibacterianos/uso terapéutico , Antiinfecciosos/uso terapéutico , Farmacorresistencia Bacteriana Múltiple , Ácido Nalidíxico/uso terapéutico , Salmonella typhi/efectos de los fármacos , Fiebre Tifoidea/tratamiento farmacológico , Adulto , Azitromicina/uso terapéutico , Ciprofloxacina/uso terapéutico , Estudios de Cohortes , Femenino , Fluoroquinolonas/uso terapéutico , Gatifloxacina , Hospitalización , Humanos , India/epidemiología , Masculino , Pruebas de Sensibilidad Microbiana , Recurrencia , Resultado del Tratamiento , Fiebre Tifoidea/epidemiología , Fiebre Tifoidea/microbiología , Adulto Joven
10.
J Appl Microbiol ; 124(6): 1393-1400, 2018 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-29457331

RESUMEN

AIM: Exploration of microbes isolated from rhizospheric soil of Crataegus oxycantha for bioactive natural products. METHODS AND RESULTS: A strain of Streptomyces sp. (C-7) was isolated from rhizospheric soil of C. oxycantha. The 16S rRNA gene sequence of strain C-7 displayed 99% sequence similarity with different Streptomyces species. The highest score was displayed for Streptomyces sp. strain Chy2-8 followed by Streptomyces violarus strain NBRC13104 and Streptomyces arenae strain ISP5293. The position of C-7 in the phylogenetic tree suggested uniqueness of the strain. Nalidixic acid (1), a quinolone antibiotic, was isolated from Streptomyces sp. strain (C-7) for the first time and characterized by NMR and chemically analysed. Compound 1 exhibited antimicrobial activity against Escherichia coli and Pseudomonas aeruginosa. The production of compound 1 was also validated by repeating fermentation of strain C-7 and compound isolation in a separate natural product laboratory with no prior information. Furthermore, Compound 1 showed a cytotoxic effect against human prostate cancer cell line PC3 with an IC50 11 µg ml-1 . CONCLUSION: To the best of our knowledge, this is the first report showing production of nalidixic acid naturally by a strain of Streptomyces sp. SIGNIFICANCE AND IMPACT OF THE STUDY: In this study, we isolated a strain of Streptomyces sp. producing nalidixic acid, which was otherwise only obtained through chemical synthesis.


Asunto(s)
Antibacterianos/biosíntesis , Crataegus/crecimiento & desarrollo , Ácido Nalidíxico/metabolismo , Microbiología del Suelo , Streptomyces/aislamiento & purificación , Streptomyces/metabolismo , Antibacterianos/química , Antibacterianos/farmacología , Línea Celular Transformada , Supervivencia Celular/efectos de los fármacos , Escherichia coli/efectos de los fármacos , Humanos , Ácido Nalidíxico/química , Ácido Nalidíxico/farmacología , Filogenia , Extractos Vegetales , Pseudomonas aeruginosa/efectos de los fármacos , ARN Ribosómico 16S/genética , Streptomyces/clasificación , Streptomyces/genética
11.
Environ Sci Pollut Res Int ; 25(22): 21430-21439, 2018 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-28921162

RESUMEN

Pectobacterium carotovorum (Pc) is a phytopathogenic strain that causes soft rot disease in potato (Solanum tuberosum L.), resulting in postharvest losses. Chemical control is effective for managing this disease, but overdoses cause adverse effects. Because farmers insist on using chemical agents for crop protection, it is necessary to develop more effective pesticides in which the active compound released can be regulated. In this context, we proposed the synthesis of ZnAl-NADS, in which nalidixic acid sodium salt (NADS) is linked to a ZnAl-NO3 layered double hydroxide (LDH) host as a nanocarrier. XRD, FT-IR, and SEM analyses confirmed the successful intercalation of NADS into the interplanar LDH space. The drug release profile indicated that the maximum release was completed in 70 or 170 min for free NADS (alone) or for NADS released from ZnAl-NADS, respectively. This slow release was attributed to strong electrostatic interactions between the drug and the anion exchanger. A modulated release is preferable to the action of the bulk NADS, showing increased effectiveness and minimizing the amount of the chemical available to pollute the soil and the water. The fitting data from modified Freundlich and parabolic diffusion models explain the release behavior of the NADS, suggesting that the drug released from ZnAl-NADS bionanohybrid was carried out from the interlamellar sites, according to the ion exchange diffusion process also involving intraparticle diffusion (coeffect). ZnAl-NADS was tested in vitro against Escherichia coli (Ec) and Pc and exhibited bacteriostatic and biocidal effects at 0.025 and 0.075 mg mL-1, respectively. ZnAl-NADS was also tested in vivo as an ecological pesticide for combating potato soft rot and was found to delay typical disease symptoms. In conclusion, ZnAl-NADS can potentially be used to control pests, infestation, and plant disease.


Asunto(s)
Aluminio/química , Ácido Nalidíxico/administración & dosificación , Pectobacterium carotovorum , Plaguicidas/síntesis química , Zinc/química , Pruebas Antimicrobianas de Difusión por Disco , Escherichia coli , Ácido Nalidíxico/química , Enfermedades de las Plantas/microbiología , Solanum tuberosum/microbiología , Espectroscopía Infrarroja por Transformada de Fourier
12.
Eur J Clin Microbiol Infect Dis ; 37(2): 271-276, 2018 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-29076047

RESUMEN

We previously found that the hospital use of tetracyclines is associated with quinolone resistance in hospital isolates of Enterobacteriaceae. Tetracyclines are heavily used in the community. Our aim was to assess whether their use in the community favors quinolone resistance in community isolates of Escherichia coli. Monthly data of community antibiotics use and E. coli quinolone resistance in a 1.3 million inhabitant French area were obtained from 2009 to 2014, and were analyzed with autoregressive integrated moving average (ARIMA) models. Quinolone use decreased from 10.1% of the total antibiotic use in 2009 to 9.3% in 2014 (trend, - 0.016; p-value < 0.0001), while tetracycline use increased from 16.5% in 2009 to 17.1% in 2014 (trend, 0.016; p < 0.0001). The mean (95% confidence interval) monthly proportions of isolates that were non-susceptible to nalidixic acid and ciprofloxacin were 14.8% (14.2%-15.5%) and 9.5% (8.8%-10.1%), respectively, with no significant temporal trend. After adjusting on quinolone use, tetracycline use in the preceding month was significantly associated with nalidixic acid non-susceptibility (estimate [SD], 0.01 [0.007]; p-value, 0.04), but not with ciprofloxacin non-susceptibility (estimate [SD], 0.01 [0.009]; p-value, 0.23). Tetracycline use in the community may promote quinolone non-susceptibility in E. coli. Decreasing both tetracycline and quinolone use may be necessary to fight against the worldwide growth of quinolone resistance.


Asunto(s)
Antibacterianos/uso terapéutico , Ciprofloxacina/uso terapéutico , Infecciones Comunitarias Adquiridas/tratamiento farmacológico , Farmacorresistencia Bacteriana Múltiple/efectos de los fármacos , Infecciones por Escherichia coli/tratamiento farmacológico , Escherichia coli/efectos de los fármacos , Ácido Nalidíxico/uso terapéutico , Tetraciclina/uso terapéutico , Adulto , Infecciones Comunitarias Adquiridas/microbiología , Escherichia coli/aislamiento & purificación , Infecciones por Escherichia coli/microbiología , Femenino , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Estudios Retrospectivos
13.
J Cell Biochem ; 119(3): 2818-2831, 2018 03.
Artículo en Inglés | MEDLINE | ID: mdl-29058787

RESUMEN

Drug resistant S. typhimurium pose important public health problem. The development of effective drugs with novel mechanism(s) of action is needed to overcome issues pertaining to drug resistance. Drug repurposing based on computational analyses is considered a viable alternative strategy to circumvent this issue. In this context, 1309 FDA-approved drugs molecules from Mantra 2.0 database were analyzed for this study, against S. typhimurium. Sixteen compounds having similar profiles of gene expression as quinolones were identified from the database, Mantra 2.0. Further, the pharmacophore characteristics of each resultant molecule were identified and compared with the features of nalidixic acid, using the PharamGist program. Subsequently, the activities of these compounds against S. typhimurium DNA gyrase were identified, using molecular docking study. Side effects analysis was also performed for the identified compounds. Molecular dynamics simulation was carried out for the compound to validate its binding efficiency. Further, characterization of screened compound revealed IC50 values in micromolar concentration range, of which flufenamic acid showed comparable in vitro activity alongside ciprofloxacin and nalidixic acid. Thus represent interesting starting points for further optimization against S. typhimurium infections. It may be noted that the results we have obtained are the first experimental evidence of flufenamic acid activity against S. typhimurium.


Asunto(s)
Proteínas Bacterianas , Girasa de ADN/química , Bases de Datos Factuales , Reposicionamiento de Medicamentos , Farmacorresistencia Bacteriana , Simulación de Dinámica Molecular , Salmonella typhimurium/enzimología , Inhibidores de Topoisomerasa II/química , Proteínas Bacterianas/antagonistas & inhibidores , Proteínas Bacterianas/química , Ciprofloxacina/química , Evaluación Preclínica de Medicamentos , Ácido Flufenámico/química , Ácido Nalidíxico/química , Quinolonas/química
14.
Microb Drug Resist ; 23(2): 177-187, 2017 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-27728774

RESUMEN

This first nationwide study was conducted to analyze the prevalence of plasmid-mediated quinolone resistance (PMQR) genes in phenotypically unselected (consecutive) clinical enterobacteria. We studied 1,058 isolates that had been consecutively collected in 66 hospitals of the WHONET-Argentina Resistance Surveillance Network. Overall, 26% of isolates were nonsusceptible to at least one of the three quinolones tested (nalidixic acid, ciprofloxacin, and levofloxacin). The overall prevalence of PMQR genes was 8.1% (4.6% for aac(6')-Ib-cr; 3.9% for qnr genes; and 0.4% for oqxA and oqxB, which were not previously reported in enterobacteria other than Klebsiella spp. from Argentina). The PMQR prevalence was highly variable among the enterobacterial species or when the different genes were considered. The prevalent PMQR genes were located in class 1 integrons [qnrB2, qnrB10, and aac(6')-Ib-cr]; in the ColE1-type plasmid pPAB19-1 or Tn2012-like transposons (qnrB19); and in Tn6238 or bracketed by IS26 and blaOXA-1 [aac(6')-Ib-cr]. The mutations associated with quinolone resistance that were located in the quinolone resistance-determining region (QRDR mutations) of gyrA, parC, and gyrB were also investigated. The occurrence of QRDR mutations was significantly associated with the presence of PMQR genes: At least one QRDR mutation was present in 82% of the PMQR-harboring isolates but in only 23% of those without PMQR genes (p < 0.0001, Fisher's Test). To the best of our knowledge, this is the first report on the prevalence of PMQR genes in consecutive clinical enterobacteria where all the genes currently known have been screened.


Asunto(s)
Antibacterianos/uso terapéutico , Farmacorresistencia Bacteriana/genética , Enterobacteriaceae/efectos de los fármacos , Enterobacteriaceae/genética , Plásmidos/genética , Quinolonas/uso terapéutico , Argentina , Proteínas Bacterianas/genética , Ciprofloxacina/uso terapéutico , Infecciones por Enterobacteriaceae/tratamiento farmacológico , Humanos , Integrones/genética , Pruebas de Sensibilidad Microbiana/métodos , Mutación/genética , Ácido Nalidíxico/uso terapéutico , Prevalencia
15.
Artículo en Inglés | WPRIM | ID: wpr-656367

RESUMEN

OBJECTIVES: Few long-term studies have been conducted on the serotype and antibiotic resistance patterns of Salmonella speices (spp.) The aim of this study was to determine the serotypes and antibiotic resistance patterns of Salmonella spp. isolated at Jeollanam-do in Korea from 2004 to 2014. METHODS: A total of 276 Salmonella samples were evaluated. Serotyping was carried out according to the Kauffmann–White scheme. Antibiotic susceptibility was determined using the Vitek II system with an AST-N169 card. RESULTS: A total of 22 different serotypes were identified, and the major serotypes were Salmonella Enteritidis (116 strains, 42.0%) and Salmonella Typhimurium (60 strains, 21.7%). The highest resistance was observed in response to nalidixic acid (43.4%), followed by ampicillin (40.5%) and tetracycline (31.6%). Resistance to nalidixic acid was detected in 81.0% of S. Enteritidis. Multidrug resistance was detected in 43.3% of Salmonella spp. S. Enteritidis and S. Typhimurium presented the highest resistance (98.3%) and multidrug resistance rate (73.3%), respectively. The most highly observed antibiotic resistance pattern among Salmonella spp. in this study was ampicillin-chloramphenicol (14 strains, 5.7%). CONCLUSION: Overall, S. Enteritidis and S. Typhimurium showed higher antibiotic resistance than the other Salmonella serotypes tested in this study. Our study will provide useful information for investigating the sources of Salmonella infections, as well as selecting effective antibiotics for treatment.


Asunto(s)
Ampicilina , Antibacterianos , Farmacorresistencia Microbiana , Resistencia a Múltiples Medicamentos , Corea (Geográfico) , Ácido Nalidíxico , Salmonella enteritidis , Infecciones por Salmonella , Salmonella typhimurium , Salmonella , Serogrupo , Serotipificación , Tetraciclina
16.
Avian Pathol ; 45(4): 501-7, 2016 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-27035748

RESUMEN

The use of antimicrobials in food animals is the major determinant for the propagation of resistant bacteria in the animal reservoir. However, other factors may also play a part, and in particular vertical spread between the generations has been suggested to be an important transmission pathway. The objective of this paper was to determine the resistance patterns of Escherichia coli isolated from newly-hatched chickens as well as to study the antibiotic pressure effect when amoxicillin was administered during their growing period. With this aim, meconium from 22 one-day-old Ross chickens was analysed. In addition, during their growth period, amoxicillin treatments at days 7, 21 and 35 were carried out. Results showed a high number of E. coli-resistant strains were isolated from the treated one-day-old chickens, and were the highest for ß-lactams group, followed by quinolone and tetracyclines. After treatment with amoxicillin, the highest percentage of resistances were detected for this antibiotic compared to the others analysed, with significant differences in resistance percentages between control and treated broilers detected in relation to ampicillin, cephalothin, streptomycin, kanamycin, gentamicin, chloramphenicol and tetracycline. Differences in resistances to ciprofloxacin and nalidixic acid between control and treated animals were not observed and there was lack of resistance for amikacin and ceftriaxone. These results suggest the possibility of vertical transmission of resistant strains to newly-hatched chicks from parent flocks, and seem to indicate that the treatment with amoxicillin increased the resistance of E. coli to other antibiotics.


Asunto(s)
Antiinfecciosos/farmacología , Pollos/microbiología , Infecciones por Escherichia coli/veterinaria , Escherichia coli/efectos de los fármacos , Transmisión Vertical de Enfermedad Infecciosa/veterinaria , Enfermedades de las Aves de Corral/microbiología , Amoxicilina/farmacología , Animales , Animales Recién Nacidos , Farmacorresistencia Bacteriana Múltiple , Escherichia coli/crecimiento & desarrollo , Escherichia coli/aislamiento & purificación , Infecciones por Escherichia coli/microbiología , Infecciones por Escherichia coli/transmisión , Masculino , Pruebas de Sensibilidad Microbiana/veterinaria , Ácido Nalidíxico/farmacología , Enfermedades de las Aves de Corral/transmisión , Quinolonas/farmacología
17.
Braz J Microbiol ; 46(3): 753-7, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26413057

RESUMEN

Quinolones and fluoroquinolones are widely used to treat uropathogenic Escherichia coli infections. Bacterial resistance to these antimicrobials primarily involves mutations in gyrA and parC genes. To date, no studies have examined the potential relationship between biochemical characteristics and quinolone resistance in uropathogenic E. coli strains. The present work analyzed the quinolone sensitivity and biochemical activities of fifty-eight lactose-negative uropathogenic E. coli strains. A high percentage of the isolates (48.3%) was found to be resistant to at least one of the tested quinolones, and DNA sequencing revealed quinolone resistant determining region gyrA and parC mutations in the multi-resistant isolates. Statistical analyses suggested that the lack of ornithine decarboxylase (ODC) activity is correlated with quinolone resistance. Despite the low number of isolates examined, this is the first study correlating these characteristics in lactose-negative E. coli isolates.


Asunto(s)
Farmacorresistencia Bacteriana Múltiple/genética , Infecciones por Escherichia coli/tratamiento farmacológico , Fluoroquinolonas/uso terapéutico , Lactosa/metabolismo , Ácido Nalidíxico/uso terapéutico , Ornitina Descarboxilasa/genética , Infecciones Urinarias/tratamiento farmacológico , Escherichia coli Uropatógena/genética , Antibacterianos/uso terapéutico , Brasil , Girasa de ADN/genética , Topoisomerasa de ADN IV/genética , Descarboxilación/genética , Descarboxilación/fisiología , Infecciones por Escherichia coli/microbiología , Humanos , Pruebas de Sensibilidad Microbiana , Ornitina/metabolismo , Infecciones Urinarias/microbiología , Escherichia coli Uropatógena/efectos de los fármacos , Escherichia coli Uropatógena/enzimología , Escherichia coli Uropatógena/aislamiento & purificación
18.
Braz. j. microbiol ; 46(3): 753-757, July-Sept. 2015. tab, ilus
Artículo en Inglés | LILACS | ID: lil-755797

RESUMEN

Quinolones and fluoroquinolones are widely used to treat uropathogenic Escherichia coli infections. Bacterial resistance to these antimicrobials primarily involves mutations in gyrA and parC genes. To date, no studies have examined the potential relationship between biochemical characteristics and quinolone resistance in uropathogenic E. coli strains. The present work analyzed the quinolone sensitivity and biochemical activities of fifty-eight lactose-negative uropathogenic E. coli strains. A high percentage of the isolates (48.3%) was found to be resistant to at least one of the tested quinolones, and DNA sequencing revealed quinolone resistant determining region gyrA and parC mutations in the multi-resistant isolates. Statistical analyses suggested that the lack of ornithine decarboxylase (ODC) activity is correlated with quinolone resistance. Despite the low number of isolates examined, this is the first study correlating these characteristics in lactose-negative E. coli isolates.

.


Asunto(s)
Humanos , Farmacorresistencia Bacteriana Múltiple/genética , Infecciones por Escherichia coli/tratamiento farmacológico , Fluoroquinolonas/uso terapéutico , Lactosa/metabolismo , Ácido Nalidíxico/uso terapéutico , Ornitina Descarboxilasa/genética , Infecciones Urinarias/tratamiento farmacológico , Escherichia coli Uropatógena/genética , Antibacterianos/uso terapéutico , Brasil , Girasa de ADN/genética , Topoisomerasa de ADN IV/genética , Descarboxilación/genética , Descarboxilación/fisiología , Infecciones por Escherichia coli/microbiología , Pruebas de Sensibilidad Microbiana , Ornitina/metabolismo , Infecciones Urinarias/microbiología , Escherichia coli Uropatógena/efectos de los fármacos , Escherichia coli Uropatógena/enzimología , Escherichia coli Uropatógena/aislamiento & purificación
19.
PLoS One ; 10(8): e0134921, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26271050

RESUMEN

OBJECTIVE: We identified a poor clinical response to treatment of cholera with a single 1 g dose of ciprofloxacin, a standard treatment for cholera. METHODS: To determine reasons for the poor response and better therapeutic approaches we examined the minimal inhibitor concentration (MIC, n = 275) and disc-diffusion zone sizes (n = 205) for ciprofloxacin and nalidixic acid of V. cholerae O1 strains isolated in Bangladesh from 1994 to 2012, and reexamined data from 161 patients infected with Vibrio cholerae O1 recruited in four clinical trials who received single- or multiple-dose ciprofloxacin for treatment of cholera and compared their clinical response to the V. cholerae O1 susceptibility. RESULTS: Although all 275 isolates of V. cholerae O1 remained susceptible to ciprofloxacin using standard MIC and disc-diffusion thresholds, the MIC90 to ciprofloxacin increased from 0.010 in 1994 to 0.475 µgm/ml in 2012. Isolates became frankly resistant to nalidixic with the MIC90 increasing from 21 µgm/ml in 1994 to >256 µgm/ml and 166 of 205 isolates from 1994 to 2005 being frankly resistant using disc-diffusion testing. Isolates resistant to nalidixic acid by disc-diffusion testing had a median ciprofloxacin MIC of 0.190 µgm/ml (10th-90th centiles 0.022 to 0.380); nalidixic acid-susceptible isolates had a median ciprofloxacin MIC of 0.002 (0.002 to 0.012).The rate of clinical success with single-dose ciprofloxacin treatment for nalidixic acid-susceptible strains was 94% (61 of 65 patients) and bacteriologic success 97% (63/65) compared to 18% (12/67) and 8% (5/67) respectively with nalidixic acid-resistant strains (P<0.001 for both comparisons). Multiple-dose treatment with ciprofloxacin had 86% and 100% clinical and bacteriologic success rates respectively in patients infected with nalidixic acid-susceptible strains of V. cholerae O1 compared to clinical success 67% and bacteriologic success 60% with nalidixic acid-resistant strains. CONCLUSIONS: Single-dose ciprofloxacin is not effective for treating cholera caused by V. cholerae O1 with diminished susceptibility to ciprofloxacin, and nalidixic acid disc-diffusion testing effectively screens for such isolates.


Asunto(s)
Cólera/tratamiento farmacológico , Ciprofloxacina/farmacología , Farmacorresistencia Bacteriana/efectos de los fármacos , Vibrio cholerae/crecimiento & desarrollo , Bangladesh , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Masculino , Ácido Nalidíxico/farmacología , Ensayos Clínicos Controlados Aleatorios como Asunto , Estudios Retrospectivos , Vibrio cholerae/aislamiento & purificación
20.
Rev Esp Quimioter ; 28(3): 139-44, 2015 Jun.
Artículo en Español | MEDLINE | ID: mdl-26032998

RESUMEN

INTRODUCTION: Quinolones are one of the types of antibiotics with higher resistance rates in the last years. At molecular level, quinolones block type II topoisomerases producing double strand breaks (DSBs). These DSBs could play a double role, as inductors of the quinolone bactericidal effects but also as mediators of the resistance and tolerance mechanisms. MATERIAL AND METHODS: In this work we have studied the molecular pathways responsible for DSBs repair in the quinolone susceptibility: the stalled replication fork reversal (recombination-dependent) (RFR), the SOS response induction, the translesional DNA synthesis (TLS) and the nucleotide excision repair mechanisms (NER). For this reason, at the European University in Madrid, we analysed the minimal inhibitory concentration (MIC) to three different quinolones in Escherichia coli mutant strains coming from different type culture collections. RESULTS: recA, recBC, priA and lexA mutants showed a significant reduction on the MIC values for all quinolones tested. No significant changes were observed on mutant strains for TLS and NER. DISCUSSION: These data indicate that in the presence of quinolones, RFR mechanisms and the SOS response could be involved in the quinolone susceptibility.


Asunto(s)
Antibacterianos/farmacología , Roturas del ADN de Doble Cadena , Reparación del ADN , ADN Bacteriano/metabolismo , Farmacorresistencia Bacteriana Múltiple/genética , Escherichia coli/efectos de los fármacos , Quinolonas/farmacología , Proteínas Bacterianas/genética , Proteínas Bacterianas/fisiología , Ciprofloxacina/farmacología , ADN Helicasas/genética , ADN Helicasas/fisiología , Replicación del ADN , ADN Bacteriano/genética , Escherichia coli/genética , Escherichia coli/aislamiento & purificación , Escherichia coli/metabolismo , Infecciones por Escherichia coli/tratamiento farmacológico , Infecciones por Escherichia coli/microbiología , Proteínas de Escherichia coli/genética , Proteínas de Escherichia coli/fisiología , Exodesoxirribonucleasa V/genética , Exodesoxirribonucleasa V/fisiología , Genes Bacterianos , Humanos , Pruebas de Sensibilidad Microbiana , Terapia Molecular Dirigida , Ácido Nalidíxico/farmacología , Norfloxacino/farmacología , Rec A Recombinasas/genética , Rec A Recombinasas/fisiología , Reparación del ADN por Recombinación , Respuesta SOS en Genética , Serina Endopeptidasas/genética , Serina Endopeptidasas/fisiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA